Title | Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Hooper AT, Shmelkov SV, Gupta S, Milde T, Bambino K, Gillen K, Goetz M, Chavala S, Baljevic M, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, Vahdat L, Evans T, Rafii S |
Journal | Circ Res |
Volume | 105 |
Issue | 2 |
Pagination | 201-8 |
Date Published | 2009 Jul 17 |
ISSN | 1524-4571 |
Keywords | Animals, Cell Line, Tumor, Disease Models, Animal, Female, Gene Expression Regulation, Developmental, Gene Knockdown Techniques, Genotype, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Morpholines, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Neovascularization, Physiologic, Oligonucleotides, Antisense, Phenotype, Promoter Regions, Genetic, Retinal Neovascularization, Signal Transduction, Skin, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Wound Healing, Zebrafish, Zebrafish Proteins |
Abstract | <p>Blood vessel formation is controlled by the balance between pro- and antiangiogenic pathways. Although much is known about the factors that drive sprouting of neovessels, the factors that stabilize and pattern neovessels are undefined. The expression of angiomodulin (AGM), a vascular endothelial growth factor (VEGF)-A binding protein, was increased in the vasculature of several human tumors as compared to normal tissue, raising the hypothesis that AGM may modulate VEGF-A-dependent vascular patterning. To elucidate the expression pattern of AGM, we developed an AGM knockin reporter mouse (AGM(lacZ/+)), with which we demonstrate that AGM is predominantly expressed in the vasculature of developing embryos and adult organs. During physiological and pathological angiogenesis, AGM is upregulated in the angiogenic vasculature. Using the zebrafish model, we found that AGM is restricted to developing vasculature by 17 to 22 hours postfertilization. Blockade of AGM activity with morpholino oligomers results in prominent angiogenesis defects in vascular sprouting and remodeling. Concurrent knockdown of both AGM and VEGF-A results in synergistic angiogenesis defects. When VEGF-A is overexpressed, the compensatory induction of the VEGF-A receptor, VEGFR2/flk-1, is blocked by the simultaneous injection of AGM morpholino oligomers. These results demonstrate that the vascular-specific marker AGM modulates vascular remodeling in part by temporizing the proangiogenic effects of VEGF-A.</p> |
DOI | 10.1161/CIRCRESAHA.109.196790 |
Alternate Journal | Circ Res |
PubMed ID | 19542015 |
PubMed Central ID | PMC2936249 |
Grant List | R01HL075234 / HL / NHLBI NIH HHS / United States P01 HL059312-090006 / HL / NHLBI NIH HHS / United States R01 HL061849-04 / HL / NHLBI NIH HHS / United States R01 HL056182 / HL / NHLBI NIH HHS / United States R01 HL061849-03S1 / HL / NHLBI NIH HHS / United States U01 HL066952-040002 / HL / NHLBI NIH HHS / United States P01 HL059312-080006 / HL / NHLBI NIH HHS / United States R01 HL075234 / HL / NHLBI NIH HHS / United States R21 HL083222-01 / HL / NHLBI NIH HHS / United States R01 HL075234-04 / HL / NHLBI NIH HHS / United States U01 HL066952 / HL / NHLBI NIH HHS / United States P01 HL067839-020004 / HL / NHLBI NIH HHS / United States P01 HL072942-010004 / HL / NHLBI NIH HHS / United States R21HL083222-02 / HL / NHLBI NIH HHS / United States P50 HL084936 / HL / NHLBI NIH HHS / United States R01 HL058707-04 / HL / NHLBI NIH HHS / United States P01 HL059312-100006 / HL / NHLBI NIH HHS / United States P01 HL072942 / HL / NHLBI NIH HHS / United States R01 HL064282 / HL / NHLBI NIH HHS / United States U01 HL066952-030002 / HL / NHLBI NIH HHS / United States P50 HL084936-010003 / HL / NHLBI NIH HHS / United States R21 HL083222-02 / HL / NHLBI NIH HHS / United States P50 HL084936-030003 / HL / NHLBI NIH HHS / United States P01 HL067839 / HL / NHLBI NIH HHS / United States R01 HL075234-03 / HL / NHLBI NIH HHS / United States U01 HL066952-020002 / HL / NHLBI NIH HHS / United States R01 HL058707-03 / HL / NHLBI NIH HHS / United States P01 HL059312-060006 / HL / NHLBI NIH HHS / United States K08 EY021171 / EY / NEI NIH HHS / United States P50 HL084936-020003 / HL / NHLBI NIH HHS / United States P01 HL059312 / HL / NHLBI NIH HHS / United States R01 HL061849-03 / HL / NHLBI NIH HHS / United States R01HL059312 / HL / NHLBI NIH HHS / United States R01 HL061849 / HL / NHLBI NIH HHS / United States R01 HL075234-02 / HL / NHLBI NIH HHS / United States R01 HL061849-05 / HL / NHLBI NIH HHS / United States P01 HL067839-050004 / HL / NHLBI NIH HHS / United States P01 HL067839-030004 / HL / NHLBI NIH HHS / United States P01 HL059312-070006 / HL / NHLBI NIH HHS / United States P50 HL084936-040003 / HL / NHLBI NIH HHS / United States R37 HL056182 / HL / NHLBI NIH HHS / United States P01 HL067839-010004 / HL / NHLBI NIH HHS / United States R01HL056182 / HL / NHLBI NIH HHS / United States R01 HL075234-01 / HL / NHLBI NIH HHS / United States R01 HL061849-02 / HL / NHLBI NIH HHS / United States U01 HL066952-050002 / HL / NHLBI NIH HHS / United States U01 HL066952-010002 / HL / NHLBI NIH HHS / United States / HHMI / Howard Hughes Medical Institute / United States P01 HL067839-040004 / HL / NHLBI NIH HHS / United States R21 HL083222 / HL / NHLBI NIH HHS / United States R01HL064282 / HL / NHLBI NIH HHS / United States |